The Evolution of T-cell Therapies for Solid Malignancies.
The Evolution of T-cell Therapies for Solid Malignancies.
复制标题
DOI：
10.1158/1078-0432.ccr-14-2675
复制
发表时间：
2015-08-01
期刊：
影响因子：
--
通讯作者：
Ahmed N
中科院分区：
文献类型：
--
作者：
Fousek K;Ahmed N
原发性抵抗性、复发性和复发性实体瘤通常对常规抗肿瘤治疗无反应。此外，在反应性肿瘤中，这些干预措施的治疗毒性范围仍然相当狭窄，因此治疗的副作用很大。靶向治疗，如过继性T细胞转移，不仅可以保护正常组织，还可以使用肿瘤细胞通常无法免疫的替代杀伤机制。由于肿瘤实质的固有异质性、肿瘤微环境的复杂性以及肿瘤发生在治疗可及性有限的地区，实体瘤的过继T细胞转移面临着独特的挑战。在这篇综述中，我们研究了各种基于T细胞的免疫疗法的最新发展，它们抗肿瘤活性背后的作用机制，它们日益增加的复杂性，以及在先前治疗实体肿瘤成功的基础上建立的前景。
Primary resistant, recurrent and relapsed solid tumors are often non-responsive to conventional anti-neoplastic therapies. Moreover, in responsive tumors, the therapeutic to toxic range of these interventions remains quite narrow, such that side effects of therapy are substantial. Targeted therapies, such as adoptive T cell transfer, not only spare normal tissues but also use alternative killing mechanisms to which the tumor cells are usually not immune. Adoptive T cell transfer for solid tumors faces unique challenges because of the inherent heterogeneity of tumor parenchyma, the complexity of the tumor microenvironment, and tumor occurrence in areas with limited therapeutic accessibility. In this review, we examine the recent evolution of various T cell-based immunotherapeutics, the mechanisms of action behind their antitumor activity, their increasing complexity, and the prospect of building on previous successes in the treatment of solid tumors.